MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 SciSparc Ltd. , a specialty clinical-stage.
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. ("MitoCareX "), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the
MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 SciSparc Ltd. , a specialty clinical-stage pharmaceutical.